DE3918082A1 - Mittel gegen autoimmunerkrankungen - Google Patents
Mittel gegen autoimmunerkrankungenInfo
- Publication number
- DE3918082A1 DE3918082A1 DE3918082A DE3918082A DE3918082A1 DE 3918082 A1 DE3918082 A1 DE 3918082A1 DE 3918082 A DE3918082 A DE 3918082A DE 3918082 A DE3918082 A DE 3918082A DE 3918082 A1 DE3918082 A1 DE 3918082A1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- alkyl
- carbon atoms
- lymphocytes
- autoimmune diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000011149 active material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ZGYRTJADPPDDMY-UHFFFAOYSA-N titanium;tetrahydrate Chemical compound O.O.O.O.[Ti] ZGYRTJADPPDDMY-UHFFFAOYSA-N 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 230000035755 proliferation Effects 0.000 description 11
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- -1 n-hexadecyl Chemical group 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N 1-octadecyl-2-methylglycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3918082A DE3918082A1 (de) | 1989-06-02 | 1989-06-02 | Mittel gegen autoimmunerkrankungen |
| GR900100406A GR1001195B (el) | 1989-06-02 | 1990-05-29 | Διαδικασια για την παρασκευη μιας φαρμακευτικης συνθεσης για τηνθεραπεια αυτοανοσων νοσηματων. |
| ES90908504T ES2060173T3 (es) | 1989-06-02 | 1990-05-31 | Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas. |
| US07/777,248 US5266564A (en) | 1989-06-02 | 1990-05-31 | Method for treating certain autoimmune diseases |
| DK90908504.5T DK0474712T3 (da) | 1989-06-02 | 1990-05-31 | Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat |
| JP2507957A JP2977894B2 (ja) | 1989-06-02 | 1990-05-31 | 自己免疫疾患用剤 |
| EP90908504A EP0474712B1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen |
| CS902689A CS276439B6 (en) | 1989-06-02 | 1990-05-31 | Pharmaceutical for treating auto-immune diseases |
| AT90908504T ATE94757T1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen. |
| PCT/EP1990/000870 WO1990014829A1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen |
| AU56706/90A AU5670690A (en) | 1989-06-02 | 1990-05-31 | Lysolecithin derivatives for treating autoimmune diseases |
| CA002056421A CA2056421C (en) | 1989-06-02 | 1990-05-31 | Agent against autoimmune diseases |
| DE90908504T DE59002863D1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen. |
| ZA904196A ZA904196B (en) | 1989-06-02 | 1990-06-01 | Process for the preparation of a pharmaceutical composition for the treatment of autoimmune diseases |
| IE198790A IE64039B1 (en) | 1989-06-02 | 1990-06-01 | Derivatives of lysolecithin for the treatment of autoimmune diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3918082A DE3918082A1 (de) | 1989-06-02 | 1989-06-02 | Mittel gegen autoimmunerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3918082A1 true DE3918082A1 (de) | 1991-01-24 |
| DE3918082C2 DE3918082C2 (enExample) | 1992-02-06 |
Family
ID=6381972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3918082A Granted DE3918082A1 (de) | 1989-06-02 | 1989-06-02 | Mittel gegen autoimmunerkrankungen |
| DE90908504T Expired - Fee Related DE59002863D1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE90908504T Expired - Fee Related DE59002863D1 (de) | 1989-06-02 | 1990-05-31 | Lysolecithinderivate zur behandlung von autoimmunerkrankungen. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5266564A (enExample) |
| EP (1) | EP0474712B1 (enExample) |
| JP (1) | JP2977894B2 (enExample) |
| AT (1) | ATE94757T1 (enExample) |
| AU (1) | AU5670690A (enExample) |
| CA (1) | CA2056421C (enExample) |
| CS (1) | CS276439B6 (enExample) |
| DE (2) | DE3918082A1 (enExample) |
| DK (1) | DK0474712T3 (enExample) |
| ES (1) | ES2060173T3 (enExample) |
| GR (1) | GR1001195B (enExample) |
| IE (1) | IE64039B1 (enExample) |
| WO (1) | WO1990014829A1 (enExample) |
| ZA (1) | ZA904196B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3941009A1 (de) * | 1989-12-12 | 1991-06-13 | Medmark Pharma Gmbh | Eliminierung von aktivierten lymphozyten |
| DE69721548T2 (de) * | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| EP1140112B1 (en) * | 1998-12-21 | 2005-03-09 | Inkeysa, S.A. | Etherlysophospholipids for the treatment of chronic inflammatory diseases |
| SE9902155L (sv) * | 1999-06-09 | 2000-12-10 | Bjoern Rydevik | Serum antibodies |
| JP2002228764A (ja) * | 2001-02-02 | 2002-08-14 | Fuji Photo Film Co Ltd | 透光性シート体検出装置 |
| JP5773569B2 (ja) | 2006-11-10 | 2015-09-02 | アルファプトーゼ ゲーエムベーハーＡｌｐｈａｐｔｏｓｅ Ｇｎｂｈ | 受容体リガンド模倣体を検出する方法 |
| ATE546133T1 (de) | 2006-11-10 | 2012-03-15 | Alphaptose Gmbh | Orale dosierform mit trisubstituierten glycerin- verbindungen |
| EP2089401B1 (en) * | 2006-11-10 | 2012-07-25 | RadioProtect Alphaptose UG (haftungsbeschränkt) & Co. KG | Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| ES2391226T3 (es) * | 2006-12-20 | 2012-11-22 | Alphaptose Gmbh | Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido |
| WO2008117062A1 (en) | 2007-03-28 | 2008-10-02 | Aker Biomarine Asa | Bioeffective krill oil compositions |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| NZ583520A (en) * | 2007-08-29 | 2012-03-30 | Aker Biomarine Asa | A new method for making krill meal |
| US20100226977A1 (en) * | 2007-08-29 | 2010-09-09 | Aker Biomarine Asa | Low viscosity phospholipid compositions |
| US8372812B2 (en) * | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| WO2013156630A1 (en) | 2012-04-20 | 2013-10-24 | Alphaptose Gmbh | S-enantiomer of a tri-substituted glycerol compound |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| PT3256003T (pt) | 2015-02-11 | 2023-02-15 | Aker Biomarine Antarctic As | Processo de extração de lipídios |
| CN114304375A (zh) | 2015-02-11 | 2022-04-12 | 阿克海洋生物南极股份公司 | 脂质组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2009342C3 (de) * | 1970-02-27 | 1980-12-18 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern |
| DE2009343C3 (de) * | 1970-02-27 | 1980-10-23 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Lysolecithinen als immunologische Adjuvantien |
| DE2619686C2 (de) * | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
| CH670763A5 (enExample) * | 1985-08-02 | 1989-07-14 | Seuref Ag |
-
1989
- 1989-06-02 DE DE3918082A patent/DE3918082A1/de active Granted
-
1990
- 1990-05-29 GR GR900100406A patent/GR1001195B/el not_active IP Right Cessation
- 1990-05-31 AT AT90908504T patent/ATE94757T1/de not_active IP Right Cessation
- 1990-05-31 JP JP2507957A patent/JP2977894B2/ja not_active Expired - Fee Related
- 1990-05-31 ES ES90908504T patent/ES2060173T3/es not_active Expired - Lifetime
- 1990-05-31 EP EP90908504A patent/EP0474712B1/de not_active Expired - Lifetime
- 1990-05-31 CA CA002056421A patent/CA2056421C/en not_active Expired - Fee Related
- 1990-05-31 DK DK90908504.5T patent/DK0474712T3/da active
- 1990-05-31 US US07/777,248 patent/US5266564A/en not_active Expired - Lifetime
- 1990-05-31 DE DE90908504T patent/DE59002863D1/de not_active Expired - Fee Related
- 1990-05-31 AU AU56706/90A patent/AU5670690A/en not_active Abandoned
- 1990-05-31 CS CS902689A patent/CS276439B6/cs not_active IP Right Cessation
- 1990-05-31 WO PCT/EP1990/000870 patent/WO1990014829A1/de not_active Ceased
- 1990-06-01 ZA ZA904196A patent/ZA904196B/xx unknown
- 1990-06-01 IE IE198790A patent/IE64039B1/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
Non-Patent Citations (1)
| Title |
|---|
| Pschyrembel, Klinisches Wörterbuch, 255. Aufl., S. 155 u. 1093 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2977894B2 (ja) | 1999-11-15 |
| US5266564A (en) | 1993-11-30 |
| CS276439B6 (en) | 1992-05-13 |
| CA2056421C (en) | 2000-10-10 |
| EP0474712A1 (de) | 1992-03-18 |
| ATE94757T1 (de) | 1993-10-15 |
| CA2056421A1 (en) | 1990-12-03 |
| DE59002863D1 (de) | 1993-10-28 |
| GR1001195B (el) | 1993-06-07 |
| GR900100406A (en) | 1991-11-15 |
| EP0474712B1 (de) | 1993-09-22 |
| ZA904196B (en) | 1991-03-27 |
| JPH04507096A (ja) | 1992-12-10 |
| AU5670690A (en) | 1991-01-07 |
| IE64039B1 (en) | 1995-06-28 |
| DE3918082C2 (enExample) | 1992-02-06 |
| DK0474712T3 (da) | 1993-11-29 |
| ES2060173T3 (es) | 1994-11-16 |
| WO1990014829A1 (de) | 1990-12-13 |
| IE901987L (en) | 1990-12-02 |
| CS268990A3 (en) | 1992-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3918082A1 (de) | Mittel gegen autoimmunerkrankungen | |
| DE69328474T2 (de) | Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose | |
| DE69434097T2 (de) | Apoptose induzierender monoklonaler antikörper | |
| DE69125185T2 (de) | Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation | |
| DE3534440A1 (de) | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes | |
| EP0248062A1 (de) | Arzeimittel. | |
| WO2000029567A1 (de) | Rekombinante glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung | |
| DE3433339A1 (de) | Zellmembran-proteine, diese enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| EP0453898A2 (de) | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen | |
| DD241271A5 (de) | Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro | |
| DE3444765A1 (de) | Immunmodulierendes arzneimittel | |
| EP1600164A2 (de) | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung | |
| EP0358130B1 (de) | Mittel mit immunsuppressiver Wirkung | |
| DE69617396T2 (de) | T-Zellen beeinflussende Peptide | |
| EP0236390B1 (de) | Mittel gegen multiple sklerose | |
| DE69423806T2 (de) | Therapeutisches Agens für NIDDM | |
| DE69116321T2 (de) | Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält | |
| DE3916417C2 (enExample) | ||
| DE2048375A1 (de) | Wirksammachung von Antibiotika | |
| DE69307895T2 (de) | Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin | |
| DE69023559T2 (de) | Derivate von Muramyldipeptid. | |
| DE2723451A1 (de) | Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln | |
| DE69233122T2 (de) | Verfahren zur Herstellung von Hybridomen | |
| DE2009342A1 (de) | Verwendung von Glycerin alkylather (1) phosphorsaure (3) monochohnestern (Äther Lysolecithine) als Mittel zur Stei gerung der natürlichen Resistenz des Or ganismus | |
| DE2546001A1 (de) | Immunostimulierende phospholipide und sie enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |